Name | nelfinavir mesylate |
---|---|
Synonyms |
Methansulfonsäure--(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-{[(3-hydroxy-2-methylphenyl)carbonyl]amino}-4-(phenylsulfanyl)butyl]decahydroisochinolin-3-carboxamid(1:1)
Nelfinavir mesylate (3S,4aS,8aS)-N-tert-Butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide methanesulfonate (1:1) (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide,methanesulfonic acid acide méthanesulfonique - (3S,4aS,8aS)-N-(1,1-diméthyléthyl)-2-[(2R,3R)-2-hydroxy-3-{[(3-hydroxy-2-méthylphényl)carbonyl]amino}-4-(phénylsulfanyl)butyl]décahydroisoquinoléine-3-carboxamide (1:1) 3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3S,4aS,8aS)-, methanesulfonate (1:1) (salt) MFCD00931436 (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]decahydroisoquinoline-3-carboxamide methanesulfonate (salt) (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-{[(3-hydroxy-2-methylphenyl)carbonyl]amino}-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide methanesulfonate (salt) Nelfinavir mesylate hydrate AZT/3TC/NLFR combination (3S-(2(2S*,3S*),3-a,4ab,8ab))-N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide monomethanesulfonate (salt) (3S,4aS,8aS)-2-[(2R,3R)-2-Hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]-N-(2-methyl-2-propanyl)decahydro-3-isoquinolinecarboxamide methanesulfonate (1:1) Nelfinavir (Mesylate) |
Description | Nelfinavir(AG-1341) is a potent and orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (Ki=2 nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection. IC50 Valur: 2 nM (Ki for HIV-1 protease) [2]Target: HIV Proteasein vitro: In vitro exposure (72 hours) of HAECs to NEL (0.25-2 μg/mL) decreased both basal (2.5-fold) and insulin-induced NO production (4- to 5-fold). NEL suppressed insulin-induced phosphorylation of both Akt and eNOS at serine residues 473 and 1177, respectively. NEL decreased tyrosine phosphorylation of IR-β, IRS-1, and PI3K. Coexposure to troglitazone (TRO; 250 nM) ameliorated the suppressive effects of NEL on insulin signaling and NO production. Coexposure to TRO also increased eNOS expression in NEL-treated HAECs [1]. AG1343 is a potent enzyme inhibitor (Ki = 2 nM) and antiviral agent (HIV-1 ED50 = 14 nM). An X-ray cocrystal structure of the enzyme-AG1343 complex reveals how the novel thiophenyl ether and phenol-amide substituents of the inhibitor interact with the S1 and S2 subsites of HIV-1 protease, respectively [2].in vivo: In vivo studies indicate that AG1343 is well absorbed orally in a variety of species and possesses favorable pharmacokinetic properties in humans [2]. |
---|---|
Related Catalog | |
References |
Boiling Point | 786.8ºC at 760 mmHg |
---|---|
Melting Point | 131-135ºC |
Molecular Formula | C33H49N3O7S2 |
Molecular Weight | 663.888 |
Flash Point | 429.7ºC |
Exact Mass | 663.301208 |
PSA | 189.95000 |
LogP | 6.05210 |
Storage condition | Store at +4°C |
~99% 159989-65-8 |
Literature: AUROBINDO PHARMA LIMITED Patent: WO2008/41087 A1, 2008 ; Location in patent: Page/Page column 6 ; |
~97% 159989-65-8 |
Literature: Japan Tobacco Inc.; Agouron Pharmaceuticals, Inc. Patent: US5962704 A1, 1999 ; |
Precursor 3 | |
---|---|
DownStream 0 |